Clinical characteristics and treatment outcomes in Hispanic/Latino patients with advanced renal cell carcinoma at a single institution.

e13738 Background: The incidence of renal cell carcinoma (RCC) is increasing, with an expected 81,610 new cases and 14,390 deaths in 2024. While clinical characteristics in patients with RCC have been well described, studies focusing on minority patients, such as Hispanic and Latino (HL), are limited. The objectives of the current study are to analyze differences in clinical, pathological, and outcome characteristics between HL and non-Hispanic Latino (NHL) pts. with advanced RCC (aRCC) in South Florida. Methods: We retrospectively reviewed clinical and pathological data from pts. with aRCC treated at Sylvester Comprehensive Cancer Center (SCCC) from 2010 to 2023. Descriptive statistics were used to summarize demographic and baseline characteristics. HL vs. NHL groups were compared using chi-square or Fisher’s exact test for categorical variables, and Wilcoxon rank-sum test for continuous variables. Time-to-event outcomes including metastasis-free survival (MFS) and overall survival (OS) were estimated using Kaplan-Meier method, and two groups were compared using the log rank rest. Results: A total of 417 patients diagnosed with aRCC who received care at SCCC were analyzed. HLs comprised 45% while NHLs represented 55% of patients with aRCC. A higher proportion of HLs presented at an earlier age (< 60y.o, 53% vs. 44%), were female (31% vs. 24%), and had a higher proportion of ISUP grade 4 tumors (47% vs. 34.8%). HLs had a significantly shorter metastasis-free survival (HR 1.48 [95% CI: 1.06-2.05]) compared to NHLs. There were no differences in the frequency of AEs from TKI, IO or IO-TKI based therapies between HLs and NHLs. HLs were less likely to achieve an objective response (CR/PR) to 1st-line therapy compared to NHLs (OR 0.54 (95% [CI: 0.31-0.94]), including HLs with non-ccRCC (OR 0.24 [95% CI: 0.07-0.81]). There was no significant correlation between ethnicity and overall survival in pts. treated with systemic therapy. HLs were less likely to achieve CR/PR to 1st-line therapy compared to NHLs (OR 0.54 [95% CI: 0.31-0.94, p=0.030]) in 217 pts. treated with 1st-line therapy, and in 55 with non-cc RCC (OR 0.24 [95% CI: 0.07-0.81, p=0.021]). There was no significant correlation between ethnicity and overall survival in pts. treated with systemic therapy. Conclusions: In our cohort, patients with aRCC presented at an earlier age and we had a higher proportion of females in HLs compared to NHLs. HLs had a higher risk of developing metastases after nephrectomy compared to NHLs and were less likely to achieve an objective response to 1st-line systemic therapy. Our results, suggesting a potentially more aggressive clinical course of aRCC in HLs in our patients, need further validation in a larger cohort. Future studies will incorporate analysis of molecular tumor characteristics, to further understand biological differences explaining outcomes observed in HL vs NHL populations with aRCC.